![]() ![]() Research is being directed toward treating other cancers such as solid tumors. In particular, immunotherapies that utilize autologous T cells modified to express chimeric antigen receptors (CARs) have achieved remarkable rates of complete response with durable, long-lasting remissions for certain hematological cancers. This study displays the capabilities of our system to address unmet needs for efficient, non-viral engineering of T cells for cell manufacturing.Ĭellular therapies have generated enthusiasm for their potential to treat a variety of inherited and acquired diseases. Finally, we demonstrate a therapeutically relevant modification of primary T cells using CRISPR/Cas9 to knockdown T cell receptor (TCR) expression. We present methods for scaling delivery that achieve an experimental throughput of 256 million cells/min. We demonstrate delivery of plasmid DNA and mRNA to primary human T cells with high efficiency and viability, such as > 95% transfection efficiency for mRNA delivery with < 2% loss of cell viability compared to control cells. Here, we present a novel electroporation platform capable of rapid and reproducible electroporation that can efficiently transfect small volumes of cells for research and process optimization and scale to volumes required for applications in cellular therapy. Electroporation has emerged as an approach for non-viral transfection of primary cells, but standard cuvette-based approaches suffer from low throughput, difficult optimization, and incompatibility with large-scale cell manufacturing. To learn more, visit /esim.Viral vectors represent a bottleneck in the manufacturing of cellular therapies. ![]() Use of eSIM in iPhone may be disabled when purchased from some carriers. Use of eSIM requires a wireless service plan (which may include restrictions on switching service providers and roaming, even after contract expiration).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |